
## Ana Espinosa

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1636078/publications.pdf Version: 2024-02-01



ANA FEDINOSA

#	Article	IF	CITATIONS
1	Automatized FACEmemory® scoring is related to Alzheimer's disease phenotype and biomarkers in early-onset mild cognitive impairment: the BIOFACE cohort. Alzheimer's Research and Therapy, 2022, 14, 43.	3.0	8
2	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. Nature Communications, 2021, 12, 3417.	5.8	140
3	From Face-to-Face to Home-to-Home: Validity of a Teleneuropsychological Battery. Journal of Alzheimer's Disease, 2021, 81, 1541-1553.	1.2	11
4	BIOFACE: A Prospective Study of Risk Factors, Cognition, and Biomarkers in a Cohort of Individuals with Early-Onset Mild Cognitive Impairment. Study Rationale and Research Protocols. Journal of Alzheimer's Disease, 2021, 83, 1233-1249.	1.2	7
5	A computerized version of the Short Form of the Face-Name Associative Memory Exam (FACEmemory®) for the early detection of Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 25.	3.0	24
6	Evaluation of macular thickness and volume tested by optical coherence tomography as biomarkers for Alzheimer's disease in a memory clinic. Scientific Reports, 2020, 10, 1580.	1.6	22
7	Association between retinal thickness and β-amyloid brain accumulation in individuals with subjective cognitive decline: Fundació ACE Healthy Brain Initiative. Alzheimer's Research and Therapy, 2020, 12, 37.	3.0	24
8	Genomeâ€wide association analysis of dementia and its clinical endophenotypes reveal novel loci associated with Alzheimer's disease and three causality networks: The GR@ACE project. Alzheimer's and Dementia, 2019, 15, 1333-1347.	0.4	111
9	Visual impairment in aging and cognitive decline: experience in a Memory Clinic. Scientific Reports, 2019, 9, 8698.	1.6	32
10	The Spanish version of Face-Name Associative Memory Exam (S-FNAME) performance is related to amyloid burden in Subjective Cognitive Decline. Scientific Reports, 2018, 8, 3828.	1.6	28
11	Genome-wide significant risk factors on chromosome 19 and the <i>APOE</i> locus. Oncotarget, 2018, 9, 24590-24600.	0.8	22
12	Usefulness of peripapillary nerve fiber layer thickness assessed by optical coherence tomography as a biomarker for Alzheimer's disease. Scientific Reports, 2018, 8, 16345.	1.6	52
13	Impact of Recruitment Methods in Subjective Cognitive Decline. Journal of Alzheimer's Disease, 2017, 57, 625-632.	1.2	26
14	Concordance between Subjective and Objective Memory Impairment in Volunteer Subjects. Journal of Alzheimer's Disease, 2015, 48, 1109-1117.	1.2	30
15	Validation of the Spanish Version of the Face Name Associative Memory Exam (S-FNAME) in Cognitively Normal Older Individuals. Archives of Clinical Neuropsychology, 2015, 30, 712-720.	0.3	22
16	A Longitudinal Follow-Up of 550 Mild Cognitive Impairment Patients: Evidence for Large Conversion to Dementia Rates and Detection of Major Risk Factors Involved. Journal of Alzheimer's Disease, 2013, 34, 769-780.	1.2	164
17	Cut-off Scores of a Brief Neuropsychological Battery (NBACE) for Spanish Individual Adults Older than 44 Years Old. PLoS ONE, 2013, 8, e76436.	1.1	69
18	Normative data of a brief neuropsychological battery for Spanish individuals older than 49. Journal of Clinical and Experimental Neuropsychology, 2012, 34, 209-219.	0.8	63

#	Article	IF	CITATIONS
19	Detection of visuoperceptual deficits in preclinical and mild Alzheimer's disease. Journal of Clinical and Experimental Neuropsychology, 2009, 31, 860-867.	0.8	52